Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05965726 · ClinicalTrials.gov registry record · Phase 2
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
A Phase 2 study, sponsored by Kanecia Obie Zimmerman.
- Completed
- Registry status
- Phase 2
- Development phase
- 964
- Enrollment target
NCT05965726 is a Phase 2 study that has completed, run by Kanecia Obie Zimmerman. The registered enrollment target is 964 participants.
The verdict
NCT05965726, a Phase 2 study, has completed, sponsored by Kanecia Obie Zimmerman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 964 participants
- Enrollment target
Study Summary
This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This sub-study is a prospective, multi-center, double-blind, randomized, controlled trial evaluating nirmatrelvir/ritonavir (Paxlovid) in two dosing durations for the treatment of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). The study is evaluating potential mechanisms of action, efficacy, and safety of antivirals and other therapeutics in individuals with PASC, according to the platform protocol objectives. The hypothesis is that persistent viral infection and/or overactive/chronic immune response and inflammation are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.
Interventions
- DRUG Ritonavir
- DRUG Paxlovid
- DRUG Nirmatrelvir-matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 964 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2025-03-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05965726
The ClinicalTrials.gov registry entry for NCT05965726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 964 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kanecia Obie Zimmerman, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ritonavir is the first listed.
NCT05965726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05965726 about?
NCT05965726 is a clinical study titled "RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms". This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This sub-study is a prospective, mul...
What is the current status of trial NCT05965726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 964 participants. The study started on 2023-07-26. Estimated completion is 2025-03-13.
What interventions are being tested in trial NCT05965726?
The interventions under investigation include: Ritonavir (DRUG), Paxlovid (DRUG), Nirmatrelvir-matching placebo (DRUG).
Who is sponsoring clinical trial NCT05965726?
This trial is sponsored by Kanecia Obie Zimmerman, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.